Tech Company Financing Transactions
Recardio Funding Round
Recardio, based in San Francisco, received $3 million from private investors.
Transaction Overview
Company Name
Announced On
11/16/2015
Transaction Type
Venture Equity
Amount
$3,000,000
Round
Series A
Investors
Proceeds Purpose
The proceeds will be used to advance a Phase 2 clinical trial for Recardio's lead therapeutic candidate, Dutogliptin, which is being developed for the treatment of acute myocardial infarction (AMI), commonly known as heart attack.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Market St. Spear Tower 36th Floor
San Francisco, CA 94105
USA
San Francisco, CA 94105
USA
Phone
Undisclosed
Website
Email Address
Overview
RECARDIO (REgenerative CARDIOvascular Therapy) is an Austrian based life science company founded in 2011. It is focusing on drug based regenerative therapeutic modalities for the treatment of cardiovascular diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Roman Schenk
Chief Financial Officer
Antonia Klopfer
Chief Information Officer
Harald Kattnig
Chief Medical Officer
Stephan Henauer
Chief Operating Officer
Frank Ahmann
Chief Scientific Officer
Darrell Nix
VP - Manufacturing
Frank Hanakam
Browse more venture capital transactions:
Prev: 11/16/2015: Qliance Medical Management venture capital transaction
Next: 11/16/2015: Butterfleye venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record tech company VC transactions. VC investment data records on this site are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs